<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; genome</title>
	<atom:link href="http://www.tapanray.in/tag/genome/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>A Sine Qua Non to Pharma Success in Digitized World</title>
		<link>http://www.tapanray.in/a-sine-qua-non-to-pharma-success-in-digitized-world/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-sine-qua-non-to-pharma-success-in-digitized-world</link>
		<comments>http://www.tapanray.in/a-sine-qua-non-to-pharma-success-in-digitized-world/#comments</comments>
		<pubDate>Mon, 16 Oct 2017 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[diagnosis]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[digitization]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[personalization]]></category>
		<category><![CDATA[Pharma. Success.Digitized. World]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sine Qua Non]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8472</guid>
		<description><![CDATA[A wind of change is now blowing at an accelerated speed &#8211; encompassing virtually anything, across the world, including India, with a varying degree, though. It leaves a profound impact on the day to day lives of many, including almost &#8230; <a href="http://www.tapanray.in/a-sine-qua-non-to-pharma-success-in-digitized-world/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-sine-qua-non-to-pharma-success-in-digitized-world/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Cancer Care: Dawns A New Era Of Precision Medicine In India</title>
		<link>http://www.tapanray.in/cancer-care-dawns-a-new-era-of-precision-medicine-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=cancer-care-dawns-a-new-era-of-precision-medicine-in-india</link>
		<comments>http://www.tapanray.in/cancer-care-dawns-a-new-era-of-precision-medicine-in-india/#comments</comments>
		<pubDate>Mon, 22 Aug 2016 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[biomarker]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[dawn]]></category>
		<category><![CDATA[diagnostics]]></category>
		<category><![CDATA[era]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[one-size-fits-all]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Pharmacogenomics]]></category>
		<category><![CDATA[Precision]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sequencing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7779</guid>
		<description><![CDATA[The concept of ‘Precision Medicine’ has started gaining increasing importance, in the treatment process of many serious diseases, such as cancer. It is now happening in many countries of the world, including India. The National Institutes of Health (NIH) of &#8230; <a href="http://www.tapanray.in/cancer-care-dawns-a-new-era-of-precision-medicine-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/cancer-care-dawns-a-new-era-of-precision-medicine-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Cancer Cure: Inching Towards The ‘Holy Grail’?</title>
		<link>http://www.tapanray.in/cancer-cure-inching-towards-the-holy-grail/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=cancer-cure-inching-towards-the-holy-grail</link>
		<comments>http://www.tapanray.in/cancer-cure-inching-towards-the-holy-grail/#comments</comments>
		<pubDate>Mon, 31 Aug 2015 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Carter]]></category>
		<category><![CDATA[cells]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[cure]]></category>
		<category><![CDATA[DNA]]></category>
		<category><![CDATA[former]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[Holy-Grail]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Jimmy]]></category>
		<category><![CDATA[magic bullet]]></category>
		<category><![CDATA[Mayo Clinic]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[programming]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[re-programming]]></category>
		<category><![CDATA[sequencing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United States]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6992</guid>
		<description><![CDATA[In a Press Conference on August 20, 2015, the 39th President of the United States, now 90-year-old  Jimmy Carter, revealed (video) that during a liver surgery earlier this month the doctors diagnosed that he has cancer. The type of cancer that he &#8230; <a href="http://www.tapanray.in/cancer-cure-inching-towards-the-holy-grail/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/cancer-cure-inching-towards-the-holy-grail/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Patient-Centric State Initiative To Revolutionize Disease Treatment</title>
		<link>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-patient-centric-state-initiative-to-revolutionize-disease-treatment</link>
		<comments>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/#comments</comments>
		<pubDate>Mon, 09 Feb 2015 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cardiovascular]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[Connect]]></category>
		<category><![CDATA[DCAT]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[genetics]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Pao]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Precision]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[Project]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Richard]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Smith]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[William]]></category>
		<category><![CDATA[‘Moonshot’ Medicine Will Let Us Down]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6374</guid>
		<description><![CDATA[In his State of the Union address, just before the recent visit to India in January 2015, President Barack Obama articulated the need to develop &#8220;Precision Medicine&#8221; in his country – a bold, giant and perhaps unprecedented State initiative to &#8230; <a href="http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Meeting Unmet Needs of Patients”: A New Direction</title>
		<link>http://www.tapanray.in/meeting-unmet-needs-of-patients-a-new-direction/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=meeting-unmet-needs-of-patients-a-new-direction</link>
		<comments>http://www.tapanray.in/meeting-unmet-needs-of-patients-a-new-direction/#comments</comments>
		<pubDate>Mon, 27 Jan 2014 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[banal]]></category>
		<category><![CDATA[direction]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[DNA]]></category>
		<category><![CDATA[evergreen]]></category>
		<category><![CDATA[genetics]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[genomics]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Meeting]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sequencing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tufts]]></category>
		<category><![CDATA[unmet]]></category>
		<category><![CDATA[warfarin]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4874</guid>
		<description><![CDATA[The much-hyped phrase of the global pharma majors &#8211; ‘meeting unmet needs of patients’, is very often used to create an aura around newer patented drugs of all kinds, from original to banal, including evergreen varieties such as: Evergreen Drug/Brand &#8230; <a href="http://www.tapanray.in/meeting-unmet-needs-of-patients-a-new-direction/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/meeting-unmet-needs-of-patients-a-new-direction/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The R&amp;D Factor: “One of the Great Myths of the Industry&#8221;</title>
		<link>http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-rd-factor-one-of-the-great-myths-of-the-industry</link>
		<comments>http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/#comments</comments>
		<pubDate>Mon, 25 Mar 2013 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1 billion]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[android]]></category>
		<category><![CDATA[Deloitte]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[economics]]></category>
		<category><![CDATA[factor]]></category>
		<category><![CDATA[Frost]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[global. CEO]]></category>
		<category><![CDATA[greatest]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[London]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[myths]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[one]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OS]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reuters]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[sequencing]]></category>
		<category><![CDATA[Sullivan]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Thomson]]></category>
		<category><![CDATA[Tuft]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[vindication]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2085</guid>
		<description><![CDATA[Yes, that is what the global CEO of one of the Pharmaceutical giants of the world commented in a very recent interview with Reuters. Adding further to this comment he said, “US $1 billion price tag for R&#38;D was an &#8230; <a href="http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Disruptive Innovation in Healthcare &#8211; Personalized Medicines</title>
		<link>http://www.tapanray.in/a-disruptive-innovation-in-healthcare-personalized-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-disruptive-innovation-in-healthcare-personalized-medicines</link>
		<comments>http://www.tapanray.in/a-disruptive-innovation-in-healthcare-personalized-medicines/#comments</comments>
		<pubDate>Mon, 21 Mar 2011 01:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[Disruptive]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Personalized. Medicines]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Profile]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sequencing]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=287</guid>
		<description><![CDATA[Tufts Center for the Study of Drug Development (Tufts University) in its publication named ‘Impact Report’, November/December 2010 articulated, “Biopharmaceutical companies are committed to researching and developing personalized medicines and within their development pipelines, 12%-50% of compounds are personalized medicines.” &#8230; <a href="http://www.tapanray.in/a-disruptive-innovation-in-healthcare-personalized-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-disruptive-innovation-in-healthcare-personalized-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
